$28.56▴ 12.22%
End-of-day close · 2026-07-27
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+2.4%year over year
Watch
Revenue growth has flattened.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
VYNE Therapeutics Inc.'s earnings-quality signal is not available yet. Revenue growth has flattened. Very low debt relative to its asset base.
Key numbers
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.